Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
featured
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Background: Peripheral blood stem cell transplantation procedures are used for people with sickle cell disease. Researchers want to improve the success and reduce the complications for these procedures. This might allow more people to have a transplant. Objective: To see if a new transplant regime is effective, safe and well …

sickle cell disease
red blood cell disorder
stroke
cell transplantation
  • 57 views
  • 22 Dec, 2020
  • 1 location
featured
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

  • 74 views
  • 25 Mar, 2021
  • 1 location
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab Busulfan and TBI With Post-Transplant Cyclophosphamide

Background CGD causes infections and inflammation. The only cure currently is a bone marrow transplant. Most often a perfectly matched bone marrow donor is used. Researchers want to see if they can lower the risks of using a mismatched donor. Objectives To see if it is safe to use a …

sirolimus
stem cell transplantation
blood test
bone marrow transplant
alemtuzumab
  • 1 views
  • 28 Jun, 2021
  • 1 location
Allograft for Sickle Cell Disease and Thalassemia

ablation. If the graft is rejected, the patient will reconstitute autologous marrow function. We will use a combination of low dose irradiation, Alemtuzumab (Campath), and sirolimus. Peripheral

  • 28 views
  • 18 Feb, 2021
  • 1 location
RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS

immunomodulatory medication. The study has two treatment arms; arm A: HSCT (hematopoietic stem cell transplantation) and arm B: alemtuzumab, a registered immunomodulatory treatment of RRMS. A pre-planned 3-year

dimethyl fumarate
natalizumab
teriflunomide
disease or disorder
MRI
  • 35 views
  • 19 Feb, 2021
  • 9 locations
Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome

The investigators designed a compassionate basis phase II study for refractory/relapsed mycosis fungoides/Sezary syndrome consisting of alemtuzumab (Campath) for primary evaluation of

mycosis fungoides and sezary syndrome
renal function test
sezary syndrome
mycosis
campath
  • 54 views
  • 07 Nov, 2020
  • 1 location
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP

antibody alemtuzumab in primary and relapsed T cell lymphoma. The investigators thus propose to investigate the value of adjuvant alemtuzumab in combination with dose dense CHOP-14 in patients

peripheral t-cell lymphoma
lymphoma
t-cell lymphoma
b-cell lymphoma
measurable disease
  • 10 views
  • 07 Nov, 2020
  • 1 location
Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation

monoclonal antibody Campath 1−H (Alemtuzumab) followed by long−term maintenance with the Calcineurin inhibitor Tacrolimus The recent development (and licensing in the UK) of an extended−release

immunosuppressants
induction therapy
tacrolimus
kidney transplant
alemtuzumab
  • 22 views
  • 07 Nov, 2020
  • 1 location
Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

RATIONALE: Immunosuppressive therapies, such as alemtuzumab and cyclosporine, may improve bone marrow function and increase blood cell counts. Giving alemtuzumab together with

immunosuppressive agents
anemia
bone marrow procedure
  • 44 views
  • 07 Nov, 2020
  • 1 location
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the

  • 0 views
  • 27 Jun, 2021
  • 1 location